Please ensure Javascript is enabled for purposes of website accessibility

Masimo Corporation Ends 2017 With Strong Pulse Oximetry Sales

By Keith Speights - Feb 28, 2018 at 6:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The maker of non-invasive monitoring technologies reported another great quarter, with record sales of its SET pulse oximeters.

Even before 2017 ended, you knew it was going to be a good year for Masimo Corporation (MASI -1.95%). When the medical device company reported its third-quarter results in October, demand for its pulse oximetry products was so strong that Masimo boosted its full-year guidance for 2017, after having already upped the guidance earlier in the year.

Masimo announced its fourth-quarter results after the market closed on Tuesday. The company officially ended 2017 on a strong note, with continued solid sales growth for its line of pulse oximetry devices. Here are the highlights from Masimo's fourth quarter.

Hand with pulse oximeter on finger

Image source: Getty Images.

Masimo results: The raw numbers

Metric 

Q4 2017 

Q4 2016 

Year-Over-Year Change

Revenue

$225.2 million $183.2 million

22.9%

Net income from continuing operations

$367,000 $215.3 million

(99.8%)

Adjusted earnings per share

$0.72 $0.45

60%

Data source: Masimo. 

What happened with Masimo this quarter?

First, let's address that glaring drop in net income reported by Masimo in the fourth quarter. The good news is that there's nothing at all to be concerned about. This huge year-over-year decline stemmed from a couple of one-time items.

Masimo recorded a non-recurring charge of $43.5 million in the fourth quarter of 2017 related to U.S. tax reform. Also, the company's prior-year period revenue total was helped by a one-time gain of $270 million from a settlement with Koninklijke Philips.

Aside from these two items, everything looked great for Masimo in the fourth quarter. The company posted solid revenue growth. In particular, sales for Masimo's rainbow pulse oximetry products increased significantly, up 42.5% year over year to $24 million.

On an adjusted basis, Masimo's bottom line improved significantly due to the revenue growth and an improving profit margin. Masimo's gross profit margin increased from 67.9% in the fourth quarter of 2016 to 68.3% in the fourth quarter of 2017.

The company's adjusted earnings per share in the fourth quarter also increased from the prior-year period thanks to $68.3 million of share buybacks in 2017. Even with these buybacks, Masimo ended the year with total cash and cash equivalents of $315.3 million, up from $306 million at the end of 2016. 

What management had to say

Masimo CEO Joe Kiani stated:

Our fourth quarter and full year 2017 results clearly illustrate the strength of our technology and hence, our business as we once again exceeded expectations for product revenues and earnings. We realized another record high for shipments of our SET Pulse Oximeters which reached 54,100 for the quarter and exceeded 200,000 for the year, a significant milestone for the company. We anticipate rising adoption of our technologies as more care providers appreciate the value they provide for patients.

Looking forward

Masimo projects total revenue in 2018 of $836 million, a 4.7% increase from 2017. Product revenue is expected to increase by 9% to $808 million. The company's 2018 guidance anticipates GAAP diluted earnings per share (EPS) of $2.90, up 23% year over year. Non-GAAP diluted EPS are expected to be $2.80, a 14% increase from 2017.

Several new products could help Masimo this year. The company received FDA clearance for home use of its Rad-97 pulse oximeter in early January. This product could enjoy high demand as the use of telehealth and home monitoring increases. Also, Masimo announced FDA clearance later in January for its next-generation Sedline brain function monitoring technology. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Masimo Corporation Stock Quote
Masimo Corporation
MASI
$137.07 (-1.95%) $-2.73
Koninklijke Philips N.V. Stock Quote
Koninklijke Philips N.V.
PHG
$21.29 (-3.18%) $0.70

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
319%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.